1 month Why Viking Therapeutics Stock Soared by Nearly 21% on ThursdayThe Motley Fool
The company provided clear evidence that it has plenty of resources to continue developing a potential blockbuster drug.
Biotech · Earnings · Nasdaq 100 · S&P 500
X